Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aquestive Therapeutics ( (AQST) ) has issued an update.
On February 2026, Aquestive Therapeutics furnished an investor presentation for institutional investors, analysts and other stakeholders, outlining its corporate strategy and clinical pipeline. The materials, made available via the company’s website and an accompanying SEC filing, detail the advancement plans and regulatory timelines for Anaphylm, Libervant and AQST-108, as well as the company’s capital position, debt obligations and reliance on sunsetting revenue from Suboxone.
The presentation also highlights significant regulatory and commercial risks, including FDA review uncertainties, potential delays, manufacturing and market-acceptance challenges and the impact of royalty and debt agreements on liquidity. Together, these disclosures underscore both the growth opportunity tied to prospective product launches and the substantial execution, financing and competitive hurdles that could affect Aquestive’s future performance and stakeholder outcomes.
The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
Overall score is pressured primarily by weak financial performance (losses, cash burn, and negative equity). Technical indicators also lean bearish (below key moving averages with negative MACD). Valuation is constrained by unprofitability and no dividend, partially offset by a relatively better earnings-call outlook supported by financing and commercialization planning.
To see Spark’s full report on AQST stock, click here.
More about Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing drug delivery technologies, notably its proprietary PharmFilm and AdrenaVerse platforms. The company targets conditions such as anaphylaxis, seizure emergencies and alopecia areata with products and candidates like Anaphylm, Libervant and AQST-108, and also derives revenue from licensed products such as Suboxone in the U.S. and abroad.
Average Trading Volume: 4,839,316
Technical Sentiment Signal: Sell
Current Market Cap: $499M
For a thorough assessment of AQST stock, go to TipRanks’ Stock Analysis page.